ABSTRACT MPE management has been changing over the years as this is due both to the technological advancement of mini-invasive surgical methods and to the change in our knowledge about this manifestation of oncology disorder. Advanced cancer disease and poor general condition in most cases do not allow large-volume and duration of surgical procedures. VATS is becoming an increasingly large share of the operating methods of treatment of spontaneous pneumothorax, thoracic trauma, acute pleural empyema, pleural effusion, benign pleural and pulmonary lesions, secondary metastatic and primary malignant lesions -pleural, pulmonary, mediastinal and bilateral location. Diagnostic and therapeutic capabilities of VATS for simultaneous diagnosis and palliative surgical treatment make it the optimal procedure in MPE management. It should be noted that the preliminary assessment of the patient's condition and local status with an estimate of survival time often undergoes a radical change after the video-assisted surgical procedure. Improvement is reported with an increase of predetermined survival time and improved performance status, which supports the application of more minimally invasive, non-intubated, "awake" single-port VATS.
INTRODUCTION
Malignant pleural effusions are an expression of an advanced oncological disease leading to a rapid deterioration in the overall condition of patients and a reduction in their physiological abilities.
In Bulgaria, according to the National Cancer Registry, issue 2017, Volume XXV, 35265 new cases of malignancies at a development rate of 1.50 were reported in 2015, while those who died from malignant diseases in 2015 were 17932, at a development rate of 1.15. Lung cancer is the most common malignancy in men -18,5% of all new cases, while in women breast cancer is the most common -26,8%. These two cancer locations are the most frequent cause for death in men and women respectively: men -in 2015 26,1% _________________________ of them died from lung and tracheal cancer; women -in 2015 17,4% died from breast cancer. Unfortunately, we do not have exact data on the average annual number of malignant pleural effusions in Bulgaria. The large number of patients with oncological diseases and the increased expectations of improving their quality of life, even after diagnosis of pleural effusion, require a change in the approach and management of MPE.
PRESENTATION
When considering the issue of MPE management, it should be noted that patients with advanced oncology disease are subject only to palliative surgical procedures aimed at improving performance status and quality of remaining life. At the same time, overall survival was unaffected or slightly affected and remains at medium range 6-12 months after the appearance of MPE.
However, we should not forget that a considerable number of patients survive up to 3, 4, 5, and sometimes more than 10 years, depending on a number of factors, such as: histological variant of primary neoplasm, adjuvant chemotherapy, target therapy, patient's comorbidity and various other predictors of survival. The treatment of MPE is palliative and aims at eliminating pleural effusion (not only passive evacuation, but also prevention of reappearance) with sufficient respiratory comfort and elimination of dyspnea symptoms. When examining the different surgical methods participating in MPE management, a number of questions need to be answered in depth, defining the indications for the use of any of them. These are: the requirement for minimal invasiveness, safety, high efficiency in diagnostic and therapeutic aspect, prospects for improvement of the methodology, possibility for quick dehospitalisation. According to many authors VATS method are in line with the answers of the above questions. Diagnosing the MPE is the most important task in patients with pleural effusion. Pleural effusion is diagnosed on the basis of medical history, objective examination findings and instrumental examinations -chest X-ray and CT scan. Cytological (pleural fluid smears) and/or pathohistological (surgical biopsies) verifications are mandatory for MPE diagnosis. Not all proven malignant primary tumors are accompanied by a malignant pleural effusion. In some cases the so called paramalignant effusions are observed. They are not subject to specific therapy and the modality of management is different with them. However, it is mandatory to differentiate them from the MPE. The term "paramalignant effusion" refers tothose effusions thatoccur on the background of primary malignant disease but are not due to metastatic process on the pleura.The reasons may be different: pneumonia with parapneumonic effusion; thoracic duct obstruction with development of chylothorax due to radiation therapy; transudative effusions due to hypoalbuminemia with hypoproteinemia, congestive heart failure, reactiveeffusion due to inflammatory causes nearby and enudates from inflammatory processes in the pleural cavity. (1) The safest way to differentiate MPE from paramalignant pleural effusion in the absence of contraindications (Karnofsky index <30, or severe concomitant comorbidity) is to conduct any of the VATS procedures -conventional or single-port, non-intubation VATS under local potentiated anesthesia. VATS methods sensitivity to histological verification is also an important indicator for the assessment and importance of video-assisted surgery methods in MPE management. According to our data, both methods -single-port and conventional provide diagnostic yield, reaching almost 100%, which makes video-assisted surgery a method of choice in MPE diagnosis. 4). Authors, comparing the diagnostic sensitivity of Abrams biopsy (blind percutaneous biopsy of the pleura) with Abrams CT-guided biopsy report the following data: 47% sensitivity, 100% specificity, for Abrams biopsy. The results obtained under CT-guided biopsy are as follows: 87% sensitivity, 100% specificity. The difference in sensitivity between Abrams biopsy and CT-guided biopsy amounts to 40% (5). In contrast, authors working with Videoassisted thoracic surgery report cytology diagnostic yield of 91-95%. (1, 6 ).In our opinion VATS diagnostic sensitivity reaches up to 100%, due to operators' experience in taking targeted biopsies from the right place and in the required depth, the mandatory waiting for express histological confirmation as well as adherence to the principle of an average number of 5-7 targeted biopsies. Video-assisted thoracic surgery appears to be the best method of diagnosis and palliative surgical treatment of malignant pleural effusions (4, 6-14). The visual assessment of changes in the pleural cavity as a visceral pleural and lung condition, an opportunity for reexpression assessment, the type and location of the lesions helps us to develop a behavioral algorithm in each case. (2, 10, 14-20) The possibility of surgically influencing the changes observed, such as partial pleurectomy with debridement and liberalization of pulmonary parenchyma with improvement of pulmonary opposition and subsequent pleurodesis is essential for improving the MPE treatment outcomes (1, 6, 8, 21). According to Raza A. et al. the importance of VATS in the management of MPЕ with suspected diaphragmatic fenestration is irreplaceable. Diaphragmatic fenestration can be suspected when there is effusion at the same time in the pleural and peritoneal cavity. Verification for the presence of diaphragmatic fenestration is performed during the procedure VATS, since the existence of such leads to failure pleurodesis. (11) It is not by accident that most authors use the expression "gold standard" when writing about Video-assisted thoracic surgery for the treatment of malignant pleural effusions (1, 14, 22) . According to us and other authors, when after evacuation of the pleural fluid the sample for re expansion is negative and the lung remains trapped, pleurodesis should not be performed. patients who have undergone VATS talc pleurodesis. They should be considered when predicting life expectancy and determining the indications for VATS talc pleurodesis (30). Thus, the requirements to be met by candidates for video-assisted surgery are as follows: Karnofsky index >30, estimated survival time exceeding 3 months, no severe accompanying comorbidity/ congestive heart failure, IV class chronic heart failure, severe hypoproteinemia and hypoalbuminemia, liver cirrhosis, III stage kidney failure/. According to us and other authors in the cases of large pleural effusions, preliminary estimated of over 2000 ml. before the VATS procedure a pre-evacuation to 1300 ml of the whole quantity is advised. Evacuation is carried out from 24 to several hours before the procedure.This decreases significantly the possibility for intra-and postoperative complications such as: pulmonary edema, ARDS and heart and circulatory disorders, and leads to temporary improvement of ventilation, blood gas and performance status indicators(12, 31, 32). This preliminary procedure also increases the percentage of eligible candidates for VATS, as well as the chances for intraoperative re-expansion of lung parenchyma. Some authors maintain the statement that the appearance of pleural effusion due to lymphomas is one of the factors that adversely affect overall survival in patients with lymphoma. The persistent pleural effusion, despite treatment, is associated with the failed outcome from the disease. Its appearance after chemotherapy and remission is a sign of relapse of the disease and leads to reduced survival. (33, 34) Another important criterion for treatment outcome is the lack of pleural effusion re-accumulation. In addition to the many factors influencing the efficiency of pleurodesis, it is of utmost importance to use the most efficient pleurodesis agents. Most authors worked on the topic described the talc as the most effective pleurodesant, with its two forms -talc poudrage and talc slurry, but their opinions on the efficacy of the two forms differ significantly. There are enough reliable studies confirming the fact that talc is considered to be the most efficient pleurodesis agent, while thoracoscopic talk pleurodesis is the most appropriate way for talc administration (10, 18, 20, 35, 36). According to Shaw P. et al. proof of this is the aggregated data from 36 randomized controlled trials with 1499 patients, meeting the meta-analysis conditions (37). Two years after this study, Tan C. et al. unify the data from 46 randomized clinical trials covering a total of 2,053 patients with malignant pleural effusion. The authors confirm that talc is the most effective pleurodesant for pleurodesis in MPЕ. In the toracoscopic talc poudrage, less recurrence of effusion is reported than in talc slurry of pleurodesis. In contraindications to performing thoracoscopy, it is appropriate to perform a talc suspension pleurodesis.
(38) The largest study is from 2016, where Clive A.O. et al. make network meta-analyzes of several randomized trials. Of the 1888 studies, 62 randomized trials were included, where a total of 3,428 patients who met the inclusion criteria. In conclusion, the authors state that, compared to other pleurodesants including doxacillin and bleomycin talc poudrage is the more effective method for pleurodesis in MPE. (29). Some of the authors argue that talc poudrage pleurodesis is not more efficient than talc slurry pleurodesis. In both cases, sustained pleurodesis is achieved, so they recommend pleurodesis with a talc suspension at the patient's bed via a pleural catheter. (39-41) Some authors examine not only the efficacy of talc as a pleurodesis agent, but its safe application as well. There are enough publications in scientific literature on the development of ARDS after thoracoscopic talk pleurodesis in MPE (42). Most authors, working on the safety of talc pleurodesis, claim that talc pleurodesis ( sterile, asbestos-free, calibrated talc with a particle size > 15 micrometers), applied as VATS talc poudrage of talc suspension with 2.5-10 g (4-6 g on average) talc is the most effective and safe method with a 93% success rate (16, 43, 44). In cases of poor performance status and/or severely manifested comorbidities, the implementation of VATS talc pleurodesis is impossible. In cases where, after evacuation of the effusion there is pleural opposition and the estimated survival is more than 3 months, iodine-povidone pleurodesis can be performed through the pleural catheter. Thus, in the patients with MPE, who fall off as candidates for the procedure VATS, can be achieved effective control of pleural effusion through iodine-povidone pleurodesis. (45, 46) The size of the pleural catheters is important for the duration of the postoperative release of pleural fluid. Large pleural catheters with a caliber over 20 charriere are not preferable. First, because they trap the lung after surgery and do not allow it to deploy adequately, and secondly, their large contact surface with the pleural sheets causes irritation and prolonged secretion. Small pleural catheters with a caliber below 12 charriere are also ineffective because of frequent occlusion of protein conglomerates. Thus, after single-port VATS, one pleural catheter remains directed to the back sinus and is taken out through the operative port, with dimensions of 14-16 charrier. In conventional VATS procedure one or two pleural catheters with dimensions 18 charriere are used through the two lower ports. (4, 12, 47) According to our experience, all drainages (pleural catheters) are put directly through the incision of the thoracic port, with no serious negatives reported and no need to use modified techniques of the thoracic port as proposed by Son B. S et al. (48) . Described and introduced by many authors over the last few years methodology of non-intubation single-port and conventional VATS, performed under potentiated local anesthesia of breathing lung has increased the possibilities for these methods to be applied to patients with contraindications for general anesthesia with one lung ventilation(6, 8, 13, 17, 49-58). All authors engaged with the topic claim, and we totally support them in our study, that there is no better way to deal with MPE than talc poudrage pleurodesis, performed together with a diagnostic assessment done by VATS methods (1, 2, 4, 6-11, 16-20, 29, 32, 37, 38, 43, 47, 50, 56, 59-62).
CONCLUSION
Advances in the development of mini-invasive thoracic surgery allowed the elaboration of new strategies to improve MPЕ management, includingmonitoring of pleural effusion, recurrent pleural evacuation,thoracostomy catheter orinternal pleural catheter, pleuroperitonealshunt (catheter) andVATS. These strategies must be consistent with the patient's overall well-being, expected survival, comorbidity, and patients take active role in the final decision. Thus VATS methods (conventional and single-port) take the lead among the methods for surgical palliative treatment in MPE management. With the inclusion of VATS-conventional and singleport in the management of MPE achieves maximum efficiency expressed in achieving lasting pleurodesis and control of pleural effusion with improving the quality of life and survival in this socially important group of patients. 
